According to the recent Life Sciences Research Outlook & Cluster Rankings report from JLL, the Greater Philadelphia region has advanced four positions in the Life Sciences Cluster Composition Matrix, which measures how each market stacks up in terms of human and physical capital. The regional improvement was due to increased and steady funding supporting the specialization of cell and gene therapy research being conducted in the area, which comes as no surprise as these therapies continue to become increasingly important options in disease treatment.
The challenge provides financial support and mentorship to selected organizations making a key difference through innovative solutions that seek to reduce the inequities among these communities. The latest J&J Health Equity Innovation Challenge recipients in Philadelphia are eCLOSE Institute, which is inspiring diversity in science through STEM education and job training for students from under-resourced schools; Maternity Care Coalition, an organization focused on reducing infant mortality rates among minority communities through its Perinatal Community Health Worker Program that has trained more than 200 perinatal community health workers; and tech startup Viora Health, which is creating a personalized engagement solution to address social and behavioral determinants for conditions like pre-diabetes, diabetes and obesity, all indications that overwhelmingly impact communities of color.
IndyGeneUS AI and the Blockchain-Secured Genomic Data Marketplace IndyGeneUS AI, which is harnessing the power of data mining and artificial intelligence to expedite the development and manufacturing of targeted therapeutics, [….]
Jonny’s back! Despite the continuation of COVID -19 through 2021, 2021 was a spectacular year for venture fundraising. Investment in every healthcare sector set records, and most experienced record IPO [….]
We have been covering the biomanufacturing workforce at length this year because it remains one of the most important topics for companies in today’s near full-employment job market.
Emergent BioSolutions Inc. (NYSE:EBS) today announced that two batches of COVID-19 vaccine manufactured by Emergent BioSolutions at its Baltimore Bayview facility were determined to be suitable for use by the U.S. Food & Drug Administration (FDA) and have been authorized as part of Johnson & Johnson’s Emergency Use Authorization (EUA).
Novavax trials highlight Maryland’s COVID-fighting complex When Novavax Inc. received $1.6 billion last year from the federal government to speed up testing and production of a coronavirus vaccine, some observers [….]
Emergent BioSolutions’ contract development and manufacturing (CDMO) business is playing a crucial role in supporting the battle against COVID-19. The company has contracted with multiple vaccine makers, including AstraZeneca and Johnson & Johnson, to manufacture the preventative medications.
Rachel is the Director of the BARDA Alliance for Johnson & Johnson Innovation, based at JLABS @ Washington, DC. In this role, she is responsible for managing the BLUE KNIGHT™ collaboration between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA). BLUE KNIGHT™ focuses on addressing public-health threats and emerging infectious diseases by supporting companies with emerging science and technology solutions that aim to improve health security and responses.
Global COVID-19 cases have been spiking in Europe and the U.S. as the predicted second wave is hitting communities hard, applying new pressure on hospital capacity and forcing local and state governments to once again tighten restrictions.
